Axel Rainer Hanauske

Summary

Country: Germany

Publications

  1. ncbi request reprint The role of protein kinase C-alpha (PKC-alpha) in cancer and its modulation by the novel PKC-alpha-specific inhibitor aprinocarsen
    A R Hanauske
    Department of Medicine, AK St Georg, Lohmuhlenstrasse 5, D 20099 Hamburg, FR Germany
    Curr Pharm Des 10:1923-36. 2004
  2. ncbi request reprint Overview of phase I/II pemetrexed studies
    Axel R Hanauske
    AK St Georg, Department of Medicine, Hamburg, Germany
    Oncology (Williston Park) 18:18-25. 2004
  3. ncbi request reprint The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor
    Kyle Holen
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, University Hospital and Clinics, 600 Highland Ave K4 528, Madison, WI 53792, USA
    Invest New Drugs 26:45-51. 2008
  4. doi request reprint [Principles and practice of clinical phase I studies]
    Axel Rainer Hanauske
    Eli Lilly and Co, Indianapolis, IN, USA
    Onkologie 31:39-45. 2008
  5. ncbi request reprint Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors
    A R Hanauske
    Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Oncologist 6:363-73. 2001
  6. doi request reprint Phase-I-study of four different schedules of pemetrexed, gemcitabine and cisplatin in patients with locally advanced or metastatic solid tumours
    Axel R Hanauske
    St Georg Hospital III, Department of Medicine, Hamburg, Germany
    Eur J Cancer 44:2444-52. 2008
  7. ncbi request reprint Correlations of mRNA expression and in vitro chemosensitivity to enzastaurin in freshly explanted human tumor cells
    Axel Rainer Hanauske
    St Georg Hospital, Lohmühlenstr 5, 20099 Hamburg, Germany
    Invest New Drugs 26:215-22. 2008
  8. ncbi request reprint In vitro chemosensitivity of freshly explanted tumor cells to pemetrexed is correlated with target gene expression
    Axel Rainer Hanauske
    Asklepios Klinik, St Georg, Lohmühlenstr 5, 20099 Hamburg, Germany
    Invest New Drugs 25:417-23. 2007
  9. ncbi request reprint Phase 1b dose escalation study of erlotinib in combination with infusional 5-Fluorouracil, leucovorin, and oxaliplatin in patients with advanced solid tumors
    Axel R Hanauske
    Department of Medicine, Asklepios Hospital St Georg, D 20099 Hamburg, Germany
    Clin Cancer Res 13:523-31. 2007
  10. ncbi request reprint Translational research with pemetrexed in breast cancer
    Axel R Hanauske
    AK St Georg, Department of Medicine, Hamburg, Germany
    Oncology (Williston Park) 18:66-9. 2004

Collaborators

Detail Information

Publications15

  1. ncbi request reprint The role of protein kinase C-alpha (PKC-alpha) in cancer and its modulation by the novel PKC-alpha-specific inhibitor aprinocarsen
    A R Hanauske
    Department of Medicine, AK St Georg, Lohmuhlenstrasse 5, D 20099 Hamburg, FR Germany
    Curr Pharm Des 10:1923-36. 2004
    ....
  2. ncbi request reprint Overview of phase I/II pemetrexed studies
    Axel R Hanauske
    AK St Georg, Department of Medicine, Hamburg, Germany
    Oncology (Williston Park) 18:18-25. 2004
    ..The studies discussed in this review demonstrate that pemetrexed is well tolerated as a single agent and will be an important contribution to combination chemotherapy regimens...
  3. ncbi request reprint The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor
    Kyle Holen
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, University Hospital and Clinics, 600 Highland Ave K4 528, Madison, WI 53792, USA
    Invest New Drugs 26:45-51. 2008
    ..FK866 is a potent inhibitor or NAD synthesis. This first-in-human study was performed to determine the maximum-tolerated dose, toxicity profile, and pharmacokinetics on a 96-h continuous infusion schedule...
  4. doi request reprint [Principles and practice of clinical phase I studies]
    Axel Rainer Hanauske
    Eli Lilly and Co, Indianapolis, IN, USA
    Onkologie 31:39-45. 2008
    ..Inclusion criteria, dose escalation schemes, and the importance of the concept of the maximum tolerable dose (MTD) are addressed together with ethical principles of exposure to novel chemical agents...
  5. ncbi request reprint Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors
    A R Hanauske
    Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Oncologist 6:363-73. 2001
    ..Currently, pemetrexed phase III trials are ongoing in mesothelioma and non-small cell lung cancer with future trials planned to explore this unique multitargeted antifolate...
  6. doi request reprint Phase-I-study of four different schedules of pemetrexed, gemcitabine and cisplatin in patients with locally advanced or metastatic solid tumours
    Axel R Hanauske
    St Georg Hospital III, Department of Medicine, Hamburg, Germany
    Eur J Cancer 44:2444-52. 2008
    ..There were no CRs, 11 PRs and 25 SDs (n=47). The PGC-combination was feasible. The recommended schedule for subsequent studies would be 1250 mg/m(2) G and 60 mg/m(2) C on d1, followed by 500 mg/m(2) P and 60 mg/m(2) C on d15...
  7. ncbi request reprint Correlations of mRNA expression and in vitro chemosensitivity to enzastaurin in freshly explanted human tumor cells
    Axel Rainer Hanauske
    St Georg Hospital, Lohmühlenstr 5, 20099 Hamburg, Germany
    Invest New Drugs 26:215-22. 2008
    ....
  8. ncbi request reprint In vitro chemosensitivity of freshly explanted tumor cells to pemetrexed is correlated with target gene expression
    Axel Rainer Hanauske
    Asklepios Klinik, St Georg, Lohmühlenstr 5, 20099 Hamburg, Germany
    Invest New Drugs 25:417-23. 2007
    ..mRNA expression of genes involved in the mechanism of action of pemetrexed was correlated with in vitro chemosensitivity of freshly explanted human tumor specimens...
  9. ncbi request reprint Phase 1b dose escalation study of erlotinib in combination with infusional 5-Fluorouracil, leucovorin, and oxaliplatin in patients with advanced solid tumors
    Axel R Hanauske
    Department of Medicine, Asklepios Hospital St Georg, D 20099 Hamburg, Germany
    Clin Cancer Res 13:523-31. 2007
    ..This trial assessed the maximum tolerated dose (MTD), safety, preliminary efficacy, and pharmacokinetics of erlotinib combined with FOLFOX...
  10. ncbi request reprint Translational research with pemetrexed in breast cancer
    Axel R Hanauske
    AK St Georg, Department of Medicine, Hamburg, Germany
    Oncology (Williston Park) 18:66-9. 2004
    ....
  11. ncbi request reprint The role of Alimta in the treatment of malignant pleural mesothelioma: an overview of preclinical and clinical trials
    Axel Rainer Hanauske
    Allgem Krankenhaus St Georg, Lohmuhlenstrasse 5, 20099 Hamburg, Germany
    Lung Cancer 45:S121-4. 2004
    ..This review summarizes preclinical and clinical data to define the future role of Alimta in the treatment of patients with MPM...
  12. ncbi request reprint Antitumor activity of enzastaurin (LY317615.HCl) against human cancer cell lines and freshly explanted tumors investigated in in-vitro [corrected] soft-agar cloning experiments
    Axel Rainer Hanauske
    Asklepios Klinik St Georg, Lohmühlenstr 5, 20099, Hamburg, Germany
    Invest New Drugs 25:205-10. 2007
    ..This warrants further clinical development in tumors which have been identified to be potentially sensitive to Enzastaurin...
  13. ncbi request reprint Pemetrexed: mRNA expression of the target genes TS, GARFT and DHFR correlates with the in vitro chemosensitivity of human solid tumors
    U Eismann
    Allgemeines Krankenhaus St Georg, Hamburg, Germany
    Int J Clin Pharmacol Ther 43:567-9. 2005
  14. ncbi request reprint Enzastaurin and pemetrexed exert synergistic antitumor activity in thyroid cancer cell lines in vitro
    O Oberschmidt
    Allgemeines Krankenhaus St Georg, Hamburg, Germany
    Int J Clin Pharmacol Ther 43:603-4. 2005
  15. doi request reprint Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/metastatic cancer
    A R Hanauske
    I Medical Department, General Hospital, St Georg, Hamburg, Germany
    Ann Oncol 20:1565-75. 2009
    ..This phase Ib study evaluated the safety, pharmacokinetics, and activity of enzastaurin either 500 mg once daily (QD) or 250 mg twice daily (b.i.d.) in combination with pemetrexed...